| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A future of cancer prevention and cures: highlights of the Centennial Meeting of the American Association for Cancer Research
|
Cho, W.C.
|
|
|
19 |
2 |
p. 205-211
|
artikel
|
| 2 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
|
Van Cutsem, E.
|
|
|
19 |
2 |
p. 332-339
|
artikel
|
| 3 |
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
|
Morschhauser, F.
|
|
|
19 |
2 |
p. 247-253
|
artikel
|
| 4 |
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study
|
Fizazi, K.
|
|
|
19 |
2 |
p. 259-264
|
artikel
|
| 5 |
Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas
|
Alarmo, E.-L.
|
|
|
19 |
2 |
p. 308-314
|
artikel
|
| 6 |
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
|
Boeck, S.
|
|
|
19 |
2 |
p. 340-347
|
artikel
|
| 7 |
Chemotherapy response evaluation with FDG–PET in patients with colorectal cancer
|
de Geus-Oei, L.F.
|
|
|
19 |
2 |
p. 348-352
|
artikel
|
| 8 |
Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma
|
Porta, C.
|
|
|
19 |
2 |
p. 353-358
|
artikel
|
| 9 |
Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab
|
Aguiar Bujanda, D.
|
|
|
19 |
2 |
p. 396-397
|
artikel
|
| 10 |
Diffuse large B-cell lymphoma of the breast: a distinct entity?
|
Bierman, P.J.
|
|
|
19 |
2 |
p. 201-202
|
artikel
|
| 11 |
Effective oral chemotherapy for breast cancer: pillars of strength
|
Findlay, M.
|
|
|
19 |
2 |
p. 212-222
|
artikel
|
| 12 |
Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma
|
Song, E.-K.
|
|
|
19 |
2 |
p. 242-246
|
artikel
|
| 13 |
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
|
Andre, F.
|
|
|
19 |
2 |
p. 315-320
|
artikel
|
| 14 |
[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study
|
Ferner, R.E.
|
|
|
19 |
2 |
p. 390-394
|
artikel
|
| 15 |
Glycemic index, glycemic load and thyroid cancer risk
|
Randi, G.
|
|
|
19 |
2 |
p. 380-383
|
artikel
|
| 16 |
HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
|
Azambuja, E.
|
|
|
19 |
2 |
p. 223-232
|
artikel
|
| 17 |
Implementation of Comprehensive National Cancer Control Program in Iran: an experience in a developing country
|
Mousavi, S.M.
|
|
|
19 |
2 |
p. 398-400
|
artikel
|
| 18 |
Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy
|
Portlock, C.S.
|
|
|
19 |
2 |
p. 254-258
|
artikel
|
| 19 |
in this issue
|
|
|
|
19 |
2 |
p. 199
|
artikel
|
| 20 |
Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?
|
Berglund, Å.
|
|
|
19 |
2 |
p. 400-402
|
artikel
|
| 21 |
Melanoma risk in association with serum leptin levels and lifestyle parameters: a case–control study
|
Gogas, H.
|
|
|
19 |
2 |
p. 384-389
|
artikel
|
| 22 |
Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
|
Prat, A.
|
|
|
19 |
2 |
p. 327-331
|
artikel
|
| 23 |
Pegfilgrastim±ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
|
von Minckwitz, G.
|
|
|
19 |
2 |
p. 292-298
|
artikel
|
| 24 |
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)
|
Castagneto, B.
|
|
|
19 |
2 |
p. 370-373
|
artikel
|
| 25 |
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies
|
Jimeno, A.
|
|
|
19 |
2 |
p. 374-379
|
artikel
|
| 26 |
Population-based study of breast cancer survival in Cote d’Or (France): prognostic factors and relative survival
|
Dabakuyo, T.S.
|
|
|
19 |
2 |
p. 276-283
|
artikel
|
| 27 |
Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group
|
Ryan, G.
|
|
|
19 |
2 |
p. 233-241
|
artikel
|
| 28 |
Prognostic factors in FIGO stage IB–IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study
|
Lee, J.-M.
|
|
|
19 |
2 |
p. 321-326
|
artikel
|
| 29 |
Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter?
|
Di Maio, M.
|
|
|
19 |
2 |
p. 402-403
|
artikel
|
| 30 |
Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial
|
Mathew, P.
|
|
|
19 |
2 |
p. 395-396
|
artikel
|
| 31 |
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
|
Rosell, R.
|
|
|
19 |
2 |
p. 362-369
|
artikel
|
| 32 |
Reply to Letter to the editor, by E. Yaman et al. (Ann Oncol)
|
Body, J.-J.
|
|
|
19 |
2 |
p. 398
|
artikel
|
| 33 |
Reply to the article “Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases” by J.-J. Body et al. (Ann Oncol 2007; 18: 1165–1171)
|
Yaman, E.
|
|
|
19 |
2 |
p. 397-398
|
artikel
|
| 34 |
Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity
|
Perik, P.J.
|
|
|
19 |
2 |
p. 359-361
|
artikel
|
| 35 |
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel
|
Domingo-Domenech, J.
|
|
|
19 |
2 |
p. 269-275
|
artikel
|
| 36 |
Table of Contents
|
|
|
|
19 |
2 |
p. ii-iv
|
artikel
|
| 37 |
The impact of the Calman-Hine report on the processes and outcomes of care for Yorkshire’s breast cancer patients
|
Morris, E.
|
|
|
19 |
2 |
p. 284-291
|
artikel
|
| 38 |
The management of non-seminomatous germ-cell tumours patients with viable malignancy at the time of RPLND
|
Huddart, R.A.
|
|
|
19 |
2 |
p. 203-204
|
artikel
|
| 39 |
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
|
Tamaskar, I.
|
|
|
19 |
2 |
p. 265-268
|
artikel
|
| 40 |
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest–Mammella Intergruppo (GONO-MIG) Group
|
Del Mastro, L.
|
|
|
19 |
2 |
p. 299-307
|
artikel
|
Tijdschrift beschrijving